You are viewing archived content
Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.
Table TDI-17. Route of administration by primary drug of clients entering treatment, 2010 or most recent year available
Part (viii) All hypnotics and sedatives outpatient clients by country and usual route of administration (%)
| Country | Inject | Smoke/inhale | Eat/drink | Sniff | Others | Route known (n) | Route unknown | |
|---|---|---|---|---|---|---|---|---|
| Belgium | 1 | 0.5 | 2.0 | 95.1 | 1.0 | 1.5 | 204 | 30 |
| Bulgaria | 12.5 | 0.0 | 87.5 | 0.0 | 0.0 | 8 | 0 | |
| Czech Republic | 3.4 | 0.0 | 96.6 | 0.0 | 0.0 | 29 | 0 | |
| Denmark | 1.2 | 0.0 | 97.6 | 1.2 | 0.0 | 82 | 4 | |
| Germany | 4.6 | 2.6 | 78.7 | 10.8 | 3.3 | 7358 | 0 | |
| Estonia | : | : | : | : | : | : | : | |
| Ireland | 0.5 | 0.0 | 99.0 | 0.0 | 0.5 | 198 | 0 | |
| Greece | 0.0 | 2.6 | 97.4 | 0.0 | 0.0 | 38 | 0 | |
| Spain | 2 | 0.4 | 1.0 | 97.9 | 0.6 | 0.1 | 945 | 18 |
| France | 2.1 | 0.0 | 91.9 | 2.7 | 3.2 | 559 | 165 | |
| Italy | 3 | 4.2 | 4.2 | 87.4 | 0.0 | 4.2 | 95 | 82 |
| Cyprus | 0.0 | 15.4 | 84.6 | 0.0 | 0.0 | 13 | 0 | |
| Latvia | 4 | 2.4 | 3.7 | 93.9 | 0.0 | 0.0 | 82 | 4 |
| Lithuania | : | : | : | : | : | : | : | |
| Luxembourg | : | : | : | : | : | : | : | |
| Hungary | 0.0 | 0.0 | 96.4 | 3.6 | 0.0 | 56 | 0 | |
| Malta | : | : | : | : | : | : | : | |
| Netherlands | 6 | 0.0 | 1.0 | 99.0 | 0.0 | 0.0 | 192 | 65 |
| Austria | 1.1 | 0.0 | 95.6 | 3.3 | 0.0 | 91 | 3 | |
| Poland | 7 | 0.0 | 0.0 | 95.7 | 0.0 | 4.3 | 23 | 0 |
| Portugal | 8 | 0.0 | 0.0 | 100.0 | 0.0 | 0.0 | 4 | 6 |
| Romania | 0.0 | 0.0 | 100.0 | 0.0 | 0.0 | 3 | 0 | |
| Slovenia | 0.0 | 0.0 | 100.0 | 0.0 | 0.0 | 5 | 1 | |
| Slovakia | 0.0 | 0.0 | 100.0 | 0.0 | 0.0 | 20 | 0 | |
| Finland | 1.6 | 0.0 | 98.4 | 0.0 | 0.0 | 61 | 0 | |
| Sweden | 1.4 | 0.0 | 97.7 | 0.9 | 0.0 | 214 | 1 | |
| United Kingdom | 9 | 0.3 | 0.9 | 98.3 | 0.3 | 0.3 | 2340 | 133 |
| Croatia | 0.0 | 0.0 | 100.0 | 0.0 | 0.0 | 42 | 0 | |
| Turkey | : | : | : | : | : | : | : | |
| Norway | 10 | 0.0 | 0.0 | 100.0 | 0.0 | 0.0 | 3 | 0 |
| Total | 3.0 | 1.9 | 86.4 | 6.6 | 2.2 | 12665 | 512 |
Notes:
: Indicates no data are available.
Percentages are of clients whose route of administration is known (n)
1 - In Belgium if the exact primary drug is not known, the generic category is recorded. In 2010 there were198 Opiates, 7 Cocaine, 7 Stimulants, 2 Hypnotics and Sedatives and 1 Hallucinogens clients with the primary exact drug unknown. Of which 24 and 5 were new clients for respectively Opiates and Stimulants.
2 - Data are from 2009. Data are from Outpatient treatment centres and some treatment units in prison (aggregated data).
3 - In 2010 around 29% of all clients and 30% of new clients were registered as not known / missing for the primary drug category. Caution should be made when comparing data over time.
4 - In 2010 Latvia submitted a new dataset with a more precise TDI EMCDDA definition. Caution should be made when comparing data with previous years.
6 - Data are from outpatient, inpatient treatment centres and Low-threshold services (aggregated data).
7 - Data are from 2009. Data presented in the table come from TDI pilot project. Caution should be made when interpreting the data.
8 - In 2010 came into implementation a new national information system implying methodological changes particularly in the registration criteria.
9 - Data are from 1st of April 2009 to 31st March 2010.
10 - In Norway the criteria for selecting and grouping cases are main ICD-10 diagnosis codes F11-F16 and F18-F19.
See also 'General notes for interpreting data' on the Explanatory notes and help page.
Source:
Reitox national reports 2011 — TDI — outpatient treatment centres.